Decreased microRNA 103 and microRNA 107 predict increased risks of acute respiratory distress syndrome and 28-day mortality in sepsis patients. Issue 25 (19th June 2020)

• Record Type: Journal Article
• Authors: Wang, Qianqian; Feng, Qiang; Zhang, Yanmin; Zhou, Shaoying; Chen, Huimin
• Other Names: Campbell. Grant R. section editor.
• Is Part Of: Medicine. Volume 99:Issue 25(2020)
• Publication Date: 2020-06-19
• Subjects: 28-day mortality -- acute respiratory distress syndrome -- disease severity -- MicroRNA-103 and MIR107 -- sepsis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000020729
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: We aimed to investigate the predictive value of microRNA 103 (MIR103) and microRNA 107 (MIR107) for acute respiratory distress syndrome (ARDS) risk, as well as their correlations with overall disease severity and prognosis in sepsis patients. Plasma samples were collected from 196 sepsis patients within 24 hours after enrollment and from 196 healthy individuals (as healthy controls (HCs)) at enrollment. Plasma MIR103 and MIR107 were detected by reverse transcription-quantitative polymerase chain reaction. MIR103 and MIR107 were both decreased in ARDS sepsis patients and non-ARDS sepsis patients compared to HCs, and were reduced in ARDS sepsis patients than non-ARDS sepsis patients. Decreased MIR103 (area under curve (AUC): 0.727, 95% confidence interval (CI): 0.619–0.835) and MIR107 (AUC: 0.694, 95% CI: 0.577–0.811) predicted increased ARDS risk in sepsis patients. Meanwhile, MIR103 and MIR107 were negatively correlated with acute pathologic and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score, serum creatinine, C-reactive protein, tumor necrosis factor, interleukin 1β, interleukin 6 and interleukin 8, while positively correlated with albumin in sepsis patients. For prognosis, 28-day mortality was increased in ARDS sepsis patients compared to non-ARDS sepsis patients. Finally, MIR103 and MIR107 were reduced in deaths than survivors of sepsis patients, and decreased MIR103 (AUC: 0.704, 95% CI: 0.626–0.782) as well as MIR107 (AUC: 0.649, 95% CI: 0.569–0.729) predicted increased 28-day mortality risk in sepsis patients. MiR-103 and MIR107 were predictive biomarkers for risks of ARDS and 28-day mortality in sepsis patients, which might improve the management of sepsis.